BioCentriq® Expands its Executive Leadership Team with Appointment of Jennifer Manning as Chief Commercial Officer
NEWARK, N.J., Oct. 3, 2023 /PRNewswire/ -- BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced today the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023.
- NEWARK, N.J., Oct. 3, 2023 /PRNewswire/ -- BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced today the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023.
- Ms. Manning added, "I am honored and excited to join the BioCentriq leadership team.
- Before joining CBM, she held the position of Executive Director, Commercial Development at Fujifilm Diosynth Biotechnologies, where she was responsible for building and leading the North American Advanced Therapies commercial development team.
- Earlier in her career, Ms. Manning held commercial roles of increasing responsibility at Lonza, Alcami Corporation, Patheon, and DSM Biologics.